A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors

NCT07036185 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

66

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastric/Gastroesophageal Junction Cancer
Breast Cancer
Colorectal Cancer
Non-small Cell Lung Cancer (NSCLC)
Bile Duct Cancer
Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: KJ015 Injection (Subcutaneous Injection)

Sponsor

Shanghai Bao Pharmaceuticals Co., Ltd.